Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic Imagingevicore Cigna Breast Imaging Coverage Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentevicorePolicy N/A

    CIGNA Medical Coverage Policies - Radiology: Breast Imaging Guidelines

    Customize your policy alerts

    Sign up for all evicore policy alerts

    Know when evicore releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers Cigna medical coverage policy guidance for breast imaging procedures and related indications used by eviCore to determine medical necessity for health plans administered by Cigna.

    Policy Summary
    Payerevicore | applies to Cigna plans
    PolicyBreast Imaging Guidelines (Radiology) — coverage criteria and coding guidance
    Policy CodePolicy N/A
    Change TypeNo material changes (routine revision)
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization through eviCore per the Cigna CPT list when requesting advanced breast imaging (e.g., bilateral contrast-enhanced breast MRI) and include documentation of the clinical indication and prior imaging results.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-09-01Effective date
    58Guideline pages (approx)
    >=20%High-risk MRI threshold
    77049/C8908Default supported MRI code
    5 yrsImplant imaging threshold
    ~15%Incidental lesion rate

    Coverage Criteria — Breast Imaging

    MRI Breast (general)

    MRI Breast coverage and coding guidance

    MRI breast requirements: Gadolinium contrast is required for evaluation of breast parenchyma; contrast is NOT medically necessary for evaluation of implant integrity in asymptomatic, average-risk individuals.

    When MRI Breast is medically necessary, CPT 77049 or HCPCS C8908 (bilateral without and with contrast) is supported unless an indication specifies noncontrast imaging (e.g., implant rupture evaluation).

    Breast reconstruction imaging

    Pre-operative imaging for breast reconstruction (free-tissue transfer flaps)

    Donor site vascular mapping: CTA or MRA of the donor body part may be performed for pre-operative planning for free-tissue transfer flaps (examples: CTA/MRA abdomen or pelvis for DIEP flap; CTA chest for TDAP flap).

    Routine use of CTA chest to evaluate recipient vessels is NOT medically necessary except when prior cardiac/vascular surgery or known vascular anomalies are present.

    Policy Summary
    Payerevicore | applies to Cigna plans
    PolicyBreast Imaging Guidelines (Radiology) — coverage criteria and coding guidance
    Policy CodePolicy N/A
    Change TypeNo material changes (routine revision)
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization through eviCore per the Cigna CPT list when requesting advanced breast imaging (e.g., bilateral contrast-enhanced breast MRI) and include documentation of the clinical indication and prior imaging results.
    SourceLink
    On This Page
    Coverage Criteria — Breast ImagingCovered Indications — Topic MapCoding — Procedure and Status TablesProvider Actions — Authorization, Documentation, BillingFrequency and Surveillance IntervalsContrast Use RulesNot Medically Necessary / InvestigationalBackground and ScopeDefinitions and Reference TermsPrior Authorization — Scope and RequirementsRevision History

    MRI after screening mammogram/US

    MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary for EITHER of the following when following a screening mammogram and/or ultrasound in asymptomatic individuals:

    Indications: 1) Requested by the treating provider to complete the screening process; OR 2) Recommended by the radiologist report; OR 3) To address a finding on the mammogram or ultrasound.

    When medical necessity is met with one of these indications, bilateral contrast-enhanced MRI (CPT 77049 or HCPCS C8908) is the supported study; alternate unilateral/bilateral MRI codes are acceptable per guideline coding rules.

    Post-biopsy or attempted biopsy imaging

    Post-biopsy MRI indications related to lesions initially seen on MRI:

    Post-biopsy follow-up: MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary at least 6 months after biopsy to document successful lesion sampling when histology is benign, non-specific, equivocal or uncertain.6 months

    Also medically necessary 6 months after attempted MRI-guided biopsy when the targeted lesion was not visualized at procedure and radiologist recommends follow-up.

    Surveillance and high-risk screening

    Follow-up protocol and high-risk screening:

    BI-RADS 3 MRI surveillance: Repeat MRI at 6 months; if still BI-RADS 3, repeat at 12, 18, and 24 months from initial imaging; after 2 years of stability, assess as benign (Category 2).6-24 months

    If repeat imaging becomes BI-RADS 1 or 2, revert to routine screening per individual's risk profile.

    High-risk annual MRI screening: Annual MRI Breast Bilateral without and with contrast is medically necessary for individuals meeting high-risk criteria (clinical lifetime-risk ≥20% by accepted models, certain high-penetrance genetic mutations, prior chest radiation per age/timing rules, and specific family history patterns).lifetime risk >=20%

    Age- and gene-specific start ages are provided in the risk factors section.

    Screening breast MRI — high-risk indications

    Covered when ANY of the following risk-based conditions are met (per document statements and referenced guideline age thresholds):

    High-risk lifetime risk: Clinical lifetime-risk >= 20% calculated by accepted models (Gail, Tyrer-Cuzick, BCSC, BOADICEA/CanRisk, BRCAPRO).>=20%

    Accepted models enumerated in document.

    Specific gene mutations with higher risk: High-penetrance gene mutations (examples: BRCA1/2, Li-Fraumeni/p53, PTEN, PALB2, CDH1, STK11, NF1, others listed) with gene-specific age-based start recommendations (e.g., BRCA start at ~25; others vary by gene).age-based per mutation

    See evidence discussion for mutation-specific age recommendations.

    Prior chest radiation: Personal history of therapeutic chest radiation when younger than age 30 — initiate MRI screening at age 25 or 8 years after completion of radiation, whichever is later.age/radiation timing rules

    Document specifies start at 25 or 8 years after radiation, whichever comes later.

    Breast density: Heterogeneously dense (Category C) or extremely dense (Category D) breasts may warrant supplemental MRI screening with age thresholds varying by guideline (ACR suggests starting at 40; NCCN suggests starting at 50 with consideration at 40).age 40-50 depending on guideline

    Document cites differing guideline positions.

    Post-biopsy or canceled MRI-guided biopsy

    Covered when ALL of the following are met:

    Post-biopsy discordant evaluation: MRI is supported when biopsy results are discordant with imaging findings or when an MRI-guided biopsy was canceled due to lesion nonvisualization and further evaluation/follow-up is needed.6-month follow-up recommended for canceled MRI-guided biopsy

    Cited study recommends 6-month follow-up MRI due to a small missed malignancy risk.

    Breast implant evaluation — coverage criteria

    Coverage varies by implant type and clinical scenario:

    Saline implants — asymptomatic: Routine MRI is not indicated for asymptomatic individuals with saline implants; there is no role for MRI in asymptomatic saline implants.

    If exam is equivocal for rupture: <30 years ultrasound; >=30 years ultrasound or diagnostic mammogram; MRI without contrast if prior imaging indeterminate.

    Silicone implants — time-based pathway: If <5 years since placement, routine advanced imaging is NOT medically necessary. If >=5 years since placement, breast ultrasound (CPT 76641/76642) is considered medically necessary; MRI Breast Bilateral without contrast (CPT 77047) is medically necessary if ultrasound is indeterminate. Repeat breast ultrasound every 2–3 years after initial negative imaging may be performed.>=5 years since implant placement

    Document provides implant-type and time-since-placement rules and sequencing.

    Equivocal exam for rupture: For silicone implants with equivocal exam, imaging with ultrasound, mammogram, and/or MRI is appropriate; MRI bilateral without contrast (CPT 77047) is medically necessary if prior imaging is indeterminate.

    For saline implants, initial imaging depends on age as above.

    Postmastectomy imaging stance

    Not routinely covered based on available evidence:

    Post-bilateral mastectomy surveillance: Routine MRI imaging for breast cancer screening following bilateral mastectomy is NOT medically necessary; surveillance MRI after nipple-sparing mastectomy increased biopsy rates without survival benefit in cited study.

    ACR Appropriateness Criteria referenced.

    Asymptomatic implant screening

    Not covered/limited:

    Asymptomatic implant screening general: Routine imaging is not medically necessary for asymptomatic individuals with implants. For silicone implants placed <5 years prior, routine advanced imaging is NOT medically necessary; for implants >=5 years, ultrasound is considered and MRI without contrast if ultrasound indeterminate.

    Cigna explicitly does NOT cover surveillance MRI for implants placed purely for cosmetic reasons.

    Physiologic nipple discharge

    Covered when the following age-based conditions are met for physiologic nipple discharge:

    Physiologic discharge imaging: Individuals <40 years: imaging is not medically necessary. Individuals >=40 years: screening mammogram is medically necessary.age

    Refer to pituitary imaging guidance if concern for prolactinoma.

    Pathologic nipple discharge

    Covered when ALL of the following age- and imaging-result-based conditions are met for pathologic nipple discharge:

    Initial imaging by age: If <30 years: initial imaging = breast ultrasound (CPT 76641/76642) with or without diagnostic mammogram. If >=30 years: initial imaging = breast ultrasound AND diagnostic mammogram.age
    Indication for MRI after initial imaging: If initial ultrasound or diagnostic mammogram is BI-RADS category 1-3, MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary.BI-RADS 1-3
    Not covered and next step: If initial ultrasound or diagnostic mammogram is BI-RADS category 4 or 5, Breast MRI is NOT medically necessary — biopsy is recommended instead.BI-RADS 4-5

    Biopsy recommended instead of MRI.

    Breast pain (mastodynia)

    Covered when criteria based on focality and age are met:

    Breast pain with other symptoms: When breast pain occurs with another breast symptom (nipple discharge, skin change, palpable mass), follow the guideline for that accompanying symptom rather than this breast pain guideline.
    Cyclical/generalized pain: If pain is cyclical and/or generalized across more than one quadrant, an up-to-date screening mammogram is medically necessary.pain distribution
    Focal pain by age: If pain is focal and age >=30: diagnostic mammogram AND breast ultrasound are medically necessary as initial imaging. If focal and age <30: breast ultrasound is medically necessary as initial imaging.age

    Advanced imaging (e.g., MRI) is NOT medically necessary for breast pain or breast abscesses.

    Alternative imaging (MRI, MBI)

    Covered alternative imaging scenarios:

    MRI following screening mammogram/US: MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary when requested by the treating provider to complete screening, recommended by the radiologist, or to address a mammogram finding.
    Molecular Breast Imaging (MBI): Molecular Breast Imaging (CPT 78800) is supported for individuals who meet criteria for MRI screening but for whom MRI is contraindicated.MRI contraindication

    See high-risk MRI screening criteria for eligibility.

    High-risk MRI screening

    Annual MRI Breast screening is medically necessary for individuals meeting specified high-risk criteria and age thresholds:

    Genetic mutations and syndromes: Specified high-penetrance genes (examples: Li-Fraumeni/p53, BRCA1/2, STK11, PTEN, CDH1, NF1, PALB2, ATM, CHEK2, BARD1, RAD51C, RAD51D) have age-based starting thresholds (e.g., BRCA1/2 start at 25).age-specific per gene

    Some genes (MSH2, MLH1, MSH6, PMS2, EPCAM, NBN) lack sufficient evidence for MRI screening.

    Personal/family history and lifetime risk: Personal history of atypia/LCIS/ADH/ALH, personal history of breast cancer at or before age 50, certain family history patterns, or estimated lifetime risk >=20% by validated models meet criteria with defined starting ages.age-specific

    Annual MRI NOT medically necessary after bilateral mastectomy even if high-risk criteria otherwise met.

    Prior chest radiation: Personal history of chest radiation when younger than age 30: begin MRI screening at age 25 or 8 years after completion of radiation, whichever is later.age/radiation interval
    Breast density: Heterogeneously dense (Category C) or extremely dense (Category D) breasts without additional risk factors: MRI screening starting at age 40 per some guidance, with NCCN suggesting age 50 (consider at 40).age 40-50

    Document cites differing guideline positions.

    High-risk supplemental screening

    Supplemental MRI/alternate imaging coverage for high-risk individuals

    High-risk supplemental MRI when ALL met: Supplemental MRI screening is supported for individuals classified as high-risk (lifetime risk >=20%) or with specified high-risk indications (e.g., prior chest irradiation) following the age/timing rules noted (e.g., start at age indicated or 10 years prior to earliest family diagnosis but not before age 25).lifetime risk >=20%

    Certain genes/variants of uncertain or intermediate penetrance are NOT sufficient evidence for MRI surveillance.

    Male screening and diagnostic criteria

    Male breast imaging

    Screening in males at increased risk: Annual clinical breast exam every 12 months is medically necessary. Annual mammogram is medically necessary for males at increased risk (e.g., BRCA2 pathogenic/likely pathogenic) starting at age 50 or 10 years before the earliest known male breast cancer in the family.start age 50 or 10 years before earliest male case

    MRI of the male breast is NOT medically necessary.

    Symptomatic male breast imaging: Diagnostic mammogram and/or breast ultrasound (CPT 76641/76642) is medically necessary for symptomatic males; MRI is not medically necessary.

    Pregnant/lactating patient imaging

    Pregnancy and lactation evaluation

    Pregnant or lactating evaluation: Breast ultrasound (CPT 76641/76642) is first-line. If a palpable mass or persistent unilateral bloody nipple discharge and ultrasound is negative or suspicious, follow with diagnostic mammogram with lead abdominal shielding. IV gadolinium is contraindicated in pregnancy; biopsy is recommended after inconclusive mammogram and ultrasound.

    MRI with gadolinium should not be used in pregnant patients; MRI may be supported in lactating women when criteria are met.

    Transgender screening criteria

    Transgender supplemental screening

    Transmasculine supplemental screening: Annual supplemental breast ultrasound (CPT 76641/76642) AND/OR MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary for transmasculine individuals who have ALL: reduction mammoplasty or no chest surgery; age >=25; and high-risk (>=20% lifetime risk).age >=25; lifetime risk >=20%

    Acceptable lifetime-risk models are Gail, Tyrer-Cuzick, BCSC, BOADICEA/CanRisk, or BRCAPRO.

    Not medically necessary in transgender scenarios: Annual breast ultrasound and/or MRI screening is NOT medically necessary for transfeminine individuals, transmasculine individuals post-bilateral mastectomy, or transmasculine individuals without mastectomies who are average or intermediate risk.

    Transmasculine high-risk annual supplemental screening

    Supplemental annual breast ultrasound and/or MRI screening is medically necessary when ALL of the following are met:

    Transmasculine high-risk screening: Individual is transmasculine (female-to-male) AND has reduction mammoplasty or no chest surgery AND is age >=25 AND is high-risk (>=20% lifetime risk).lifetime risk >=20%

    Document requires objective lifetime-risk calculation using accepted models and documentation of surgical history and transmasculine status.

    Not medically necessary: supplemental screening (transgender populations)

    Annual supplemental ultrasound and/or MRI screening is NOT medically necessary for ANY of the following:

    Not indicated groups: Transfeminine (male-to-female) individuals; transmasculine individuals who have had bilateral mastectomies; transmasculine individuals without mastectomies who are at average or intermediate risk.

    Supplemental MRI/ultrasound screening reserved only for the specified high-risk transmasculine group.

    Breast mass imaging criteria

    For evaluation of a breast mass:

    Initial imaging by age: If >=30 years: diagnostic mammogram AND breast ultrasound are medically necessary as initial imaging. If <30 years: breast ultrasound is medically necessary as initial imaging.

    MRI is NOT medically necessary to determine biopsy recommendations for lesions that can be readily biopsied on physical exam.

    BI-RADS 4 or 5: If diagnostic mammogram or ultrasound is BI-RADS category 4 or 5, Breast MRI is NOT medically necessary; biopsy is recommended.BI-RADS 4 or 5

    MRI should not be used to bypass biopsy.

    Palpable masses: MRI is not medically necessary to determine biopsy recommendations for suspicious or indeterminate lesions that can be readily biopsied on physical exam (e.g., palpable masses).

    Proceed to biopsy rather than MRI.

    Skin changes imaging criteria

    For skin changes of the breast:

    Initial imaging: Diagnostic mammogram with or without breast ultrasound (CPT 76641/76642) is the medically necessary initial imaging.
    BI-RADS 1-3 on initial imaging: If initial imaging is BI-RADS category 1-3, bilateral Breast MRI without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary.BI-RADS 1-3

    If initial imaging is BI-RADS 4-5, MRI is not indicated and biopsy is recommended.

    Benign core biopsy: If a core needle biopsy is performed and is benign, bilateral Breast MRI without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary to further evaluate extent if clinically indicated.benign core needle biopsy

    Advanced imaging is NOT medically necessary for breast abscesses.

    Nipple inversion/retraction imaging criteria

    When no palpable mass is present and nipple inversion/retraction is acquired/new onset:

    Initial imaging by age: If >=30 years: diagnostic mammogram and breast ultrasound are medically necessary as initial imaging. If <30 years: breast ultrasound with or without diagnostic mammogram is medically necessary.

    Follow nipple discharge or skin change pathways if those symptoms are present.

    BI-RADS 1-3 but clinically suspicious: If initial imaging is BI-RADS category 1, 2, or 3 but clinically suspicious, bilateral Breast MRI without and with contrast (CPT 77049 or HCPCS C8908) is medically necessary.BI-RADS 1-3 + clinical suspicion

    If BI-RADS 4-5, biopsy recommended and MRI not medically necessary.

    Pre-operative MRI for malignant phyllodes

    Covered when ALL of the following are met

    Primary criteria: 1) A diagnosis of malignant phyllodes tumor previously established by tissue diagnosis (percutaneous core biopsy or excisional biopsy; FNA is not acceptable). 2) MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is requested pre-operatively to establish extent of disease and assess resectability.

    MRI is supported for pre-operative staging of malignant phyllodes; MRI is NOT useful to distinguish phyllodes from fibroadenoma.

    No explicit coverage exclusions are listed in the table of contents excerpt for this guideline. The TOC entries enumerate sections (e.g., Nipple Discharge/Galactorrhea, Breast Pain, Alternative Breast Imaging Approaches, Breast Imaging in Males, Breast Evaluation in Pregnant or Lactating Females) but do not by themselves state specific exclusions.

    Per the MRI Breast guidance, gadolinium contrast is required when evaluating breast parenchyma, but the guideline explicitly states that the use of gadolinium contrast is NOT medically necessary for the evaluation of implant integrity in asymptomatic, average-risk individuals; when implant integrity imaging is indicated, a non-contrast MRI (CPT 77047) is specified for rupture evaluation.

    Routine CTA of the chest to evaluate recipient vessels for flap reconstruction is described as NOT medically necessary, with limited exceptions for prior chest surgery or known vascular anomalies. Likewise, routine bilateral breast MRI following bilateral mastectomy is stated as NOT medically necessary even if other high-risk screening criteria would otherwise apply.

    Cigna does NOT cover surveillance MRI for breast implants that were placed solely for cosmetic purposes; surveillance imaging for implants is otherwise guided by implant type and clinical scenario.

    Covered Indications — Topic Map

    The document contains multiple breast imaging indication sections as listed in the table of contents.

    The document contains multiple breast imaging indication sections as listed in the table of contents.

    TOC sections: Includes sections such as MRI Breast Coding, Breast Reconstruction, MRI Breast Indications, Nipple Discharge/Galactorrhea, Breast Pain (Mastodynia), Alternative Breast Imaging, Breast Imaging in Males, Breast Evaluation in Pregnant or Lactating Females, and Transgender Breast Cancer Supplemental Screening.

    See table of contents for full section listing.

    Coding — Procedure and Status Tables

    MRI Breast and related procedure codesmixed
    77049MRI Breast Bilateral, including CAD, without and with contrast
    C8908HCPCS MRI Breast Bilateral, without and with contrast
    77047MRI Breast Bilateral, without contrast
    C8937CAD including computer algorithm analysis of MRI Breast data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation
    763763D rendering; interpretation and reporting (note: not to be used with MRI Breast when CAD automatically performs 3D imaging)
    763773D rendering; image processing (note: not to be used with MRI Breast when CAD automatically performs 3D imaging)
    19085MRI-guided breast biopsy (includes imaging component and needle placement)
    77021MR guidance for needle placement (not appropriate to bill in addition to CPT 19085)
    19086Addition for multiple lesions in breast biopsy (additional lesion)
    CTA/MRA codes for reconstruction planningCPT
    74175CTA Abdomen and/or Pelvis
    72191CTA Pelvis
    74174CTA Abdomen (alternative)
    74185MRA Abdomen and/or Pelvis with and without IV contrast
    72198MRA Pelvis
    71275CTA Chest
    Covered CPT/HCPCS codes for MRI breastmixedCovered
    77049MRI Breast Bilateral without and with contrast
    C8908MRI Breast Bilateral without and with contrast (HCPCS)
    77046MRI Breast Unilateral without contrast
    77047MRI Breast Bilateral without contrast
    77048MRI Breast Unilateral without and with contrast
    C8903MRI Breast Unilateral with contrast (HCPCS)
    C8905MRI Breast Unilateral without and with contrast (HCPCS)
    C8906MRI Breast Bilateral with contrast (HCPCS)
    Implant evaluation and related ultrasound/MRI CPT codesCPTCovered
    76641Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; complete
    76642Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited or follow-up
    77047Magnetic resonance (e.g., breast), without contrast material, bilateral
    Procedure Codes mentionedCPT | HCPCS | mixed
    76641Breast ultrasound, unilateral, real-time with image documentation; complete
    76642Breast ultrasound, unilateral, real-time with image documentation; limited
    77049Magnetic resonance (e.g., breast), bilateral without and with contrast
    C8908HCPCS alternative for breast MRI (bilateral without and with contrast)
    78800Molecular breast imaging (MBI)
    0633TCT Breast (proprietary CPT series listed as examples)
    0634TCT Breast
    0635TCT Breast
    0636TCT Breast
    0637TCT Breast
    1–10 of 11
    1/2
    Investigational CT breast codesCPTNot Covered
    CPT 0633TCT Breast (per document listing)
    CPT 0634TCT Breast (per document listing)
    CPT 0635TCT Breast (per document listing)
    CPT 0636TCT Breast (per document listing)
    CPT 0637TCT Breast (per document listing)
    CPT 0638TCT Breast (per document listing)
    Common breast ultrasound and MRI codesmixedCovered
    CPT 76641Ultrasound, breast, unilateral, complete
    CPT 76642Ultrasound, breast, bilateral, complete
    CPT 77049Magnetic resonance imaging, breast, bilateral, without and with contrast
    HCPCS C8908MRI breast bilateral w/wo contrast (HCPCS representation in document)
    Positron-emission mammography requestsCPTNot Covered
    CPT 78811PET scan of the breast (referenced as how providers request PEM)
    Diagnostic/Screening Ultrasound CodesCPTCovered
    76641Ultrasound, breast, unilateral or bilateral; complete
    76642Ultrasound, breast, unilateral or bilateral; limited
    Breast MRI CodesCPTCovered
    77049Magnetic resonance (e.g., breast), bilateral, without and with contrast material
    Breast MRI HCPCSHCPCSCovered
    C8908Breast MRI bilateral without and with contrast (HCPCS equivalent)
    3D Rendering CodesCPTNot Covered
    763763D rendering with interpretation and reporting of CT, MR, ultrasound, or other tomographic modality; not used with 3D mammography or MRI Breast per guideline
    763773D rendering with interpretation and reporting, additional session
    Covered CPT/HCPCS Codes for indicated MRImixedCovered
    77049MRI Breast Bilateral without and with contrast
    C8908HCPCS equivalent — MRI Breast Bilateral without and with contrast
    Implant imaging timing (silicone)
    Implant age threshold (silicone)>= 5 years since implant placement
    Initial action if >=5 yearsBreast ultrasound (CPT 76641/76642) is considered medically necessary
    If ultrasound indeterminateMRI Breast Bilateral without contrast (CPT 77047) is medically necessary

    Provider Actions — Authorization, Documentation, Billing

    Prior Authorization

    eviCore review required for specified high‑tech imaging

    Some high‑tech imaging procedures for Cigna members are reviewed by eviCore; providers must consult the Cigna CPT code list to determine which procedures require eviCore review.

    Note

    Prior authorization (TOC — no details)

    This table of contents excerpt does not describe specific prior authorization procedures or submission requirements.

    Note

    Prior authorization (not specified in excerpt)

    The provided excerpt contains section headings and page references but does not specify operational prior authorization rules or steps.

    Prior Authorization

    Follow eviCore/Cigna prior authorization process

    These guidelines apply to services and supplies managed by eviCore for Cigna; providers must follow eviCore/Cigna prior authorization processes as outlined by the Cigna CPT list when applicable.

    Prior Authorization

    Prior authorization for breast MRI — supported codes

    Prior authorization applies to breast MRI studies; when medically necessary the supported default study is bilateral MRI without and with contrast (CPT 77049 or HCPCS C8908).

    • Supported bilateral contrast study: CPT 77049 or HCPCS C8908
    • Unilateral or non‑contrast codes acceptable only when specified by indication
    Prior Authorization

    Prior authorization required for implant imaging pathways

    Prior authorization is required for imaging requested for implant evaluation pathways; ultrasound (CPT 76641/76642), diagnostic mammography, or MRI Breast Bilateral without contrast (CPT 77047) must be authorized when indicated by the guideline.

    • Ultrasound codes: CPT 76641, CPT 76642
    • Non‑contrast MRI for implant evaluation: CPT 77047
    Prior Authorization

    Prior authorization for MRI and MBI per medical‑necessity criteria

    When MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is being requested per medical‑necessity criteria (e.g., to complete screening, radiologist recommendation, or to address a mammogram/US finding), prior authorization applies; Molecular Breast Imaging (CPT 78800) is supported when MRI is contraindicated and also requires authorization.

    • MRI bilateral with/without contrast: CPT 77049 or HCPCS C8908
    • MBI code: CPT 78800 (when MRI contraindicated)
    Prior Authorization

    Prior authorization for investigational CT breast and alternative modalities

    CT breast procedures (CPT 0633T–0638T) and other alternative breast imaging modalities are considered investigational; expect that prior authorization will be required and that requests may be denied without compelling supporting evidence.

    • Investigational CT Breast CPT codes: 0633T–0638T
    • Other investigational modalities include scintimammography, BSGI, PEM, thermography, impedance mammography, cone beam CT
    Prior Authorization

    Prior authorization for transmasculine supplemental screening

    Requests for supplemental ultrasound (CPT 76641/76642) and/or MRI breast (CPT 77049 or HCPCS C8908) in transmasculine individuals who meet ALL specified risk criteria require documentation and prior authorization per the guideline.

    • Acceptable ultrasound codes: CPT 76641, CPT 76642
    • Acceptable MRI codes: CPT 77049 or HCPCS C8908
    Prior Authorization

    Prior authorization required for advanced imaging and 3D rendering

    Advanced imaging codes (e.g., bilateral breast MRI CPT 77049/HCPCS C8908; ultrasound CPT 76641/76642; 3D rendering CPT 76376/76377) require prior authorization and must meet the clinical criteria described in the guideline.

    • 3D rendering (CPT 76376/76377) requests require authorization and have specific exclusions
    • Prior authorization required for advanced imaging modalities listed
    Prior Authorization

    Prior authorization for pre‑operative bilateral breast MRI (malignant phyllodes)

    Prior authorization is expected when bilateral contrast‑enhanced breast MRI (CPT 77049 or HCPCS C8908) is requested pre‑operatively to establish extent of disease for a biopsy‑proven malignant phyllodes tumor; the request must cite prior tissue diagnosis.

    • Supported codes for pre‑operative staging: CPT 77049 or HCPCS C8908
    • Request must document prior tissue diagnosis (core or excisional biopsy)
    Note

    Prior authorization (references section — none stated)

    This references section does not state any additional prior authorization requirements.

    Step Therapy

    MRI BI‑RADS 3 surveillance schedule

    For MRI‑detected BI‑RADS 3 lesions, perform repeat MRI at 6 months; if still BI‑RADS 3, continue MRI at 12, 18, and 24 months from the initial imaging, and consider the lesion benign after 2 years of stability.

    • Surveillance schedule: 6, 12, 18, and 24 months
    • Assess as benign (BI‑RADS 2) after 2 years of stability
    Step Therapy

    Imaging sequence for implant evaluation — start with ultrasound/mammogram

    For implant evaluation, follow a sequential imaging approach: ultrasound (preferred in younger individuals) and/or diagnostic mammogram first; if prior imaging is indeterminate, MRI Breast Bilateral without contrast (CPT 77047) is medically necessary.

    • Initial imaging: ultrasound (CPT 76641/76642) ± diagnostic mammogram depending on age
    • If indeterminate: non‑contrast MRI CPT 77047
    Step Therapy

    Pregnancy imaging — ultrasound first, avoid gadolinium

    In pregnant patients, breast ultrasound (CPT 76641/76642) is first‑line; if ultrasound is negative or suspicious for a palpable mass or persistent bloody nipple discharge, follow with diagnostic mammogram with abdominal shielding rather than proceeding directly to gadolinium‑enhanced MRI, since IV gadolinium is contraindicated in pregnancy.

    • First‑line: breast ultrasound (CPT 76641/76642)
    • If further evaluation needed: diagnostic mammogram with shielding; avoid IV gadolinium in pregnancy
    Denial Risk

    Specify a medically necessary indication when requesting breast MRI

    Requests for MRI Breast must specify a medically necessary indication (for example: to complete screening when requested by the treating provider, recommended by the radiologist, or to address a finding on mammogram/US); lack of such indication may lead to denial.

    • Supported reasons include: provider request to complete screening, radiologist recommendation, or to address a mammogram finding
    Denial Risk

    Implant surveillance for cosmetic implants is not covered

    Surveillance MRI for breast implants placed solely for cosmetic reasons is not covered by Cigna and may be denied.

    Denial Risk

    Investigational alternative imaging modalities — denial risk

    Requests for alternative breast imaging techniques listed as investigational (e.g., scintimammography, BSGI, PEM, thermography, impedance mammography, CT Breast, cone beam CT) are considered investigational and may be denied for screening or diagnostic use.

    • Investigational modalities include CT Breast (CPT 0633T–0638T), PEM, BSGI, scintimammography, thermography, impedance mammography, cone beam CT
    Denial Risk

    Gadolinium contrast contraindicated in pregnancy — potential denial

    Requests for breast MRI with IV gadolinium in pregnant patients may be denied because IV gadolinium is contraindicated in pregnancy.

    Denial Risk

    Do not use MRI to avoid biopsy for readily biopsied palpable masses

    Do not request breast MRI to determine biopsy recommendations for palpable masses that can be readily biopsied; proceed to biopsy rather than MRI, as MRI for this purpose is not supported and may be denied.

    Denial Risk

    MRI not supported when prior imaging is BI‑RADS 4–5 — biopsy indicated

    Requests for Breast MRI when prior diagnostic mammogram or ultrasound demonstrates BI‑RADS category 4 or 5 will be denied because MRI is not medically necessary for lesions that require biopsy.

    Denial Risk

    Pre‑op bilateral MRI for malignant phyllodes requires prior tissue diagnosis

    Bilateral contrast‑enhanced breast MRI for pre‑operative staging of malignant phyllodes is supported only when a prior tissue diagnosis of malignant phyllodes has been established by percutaneous core biopsy or excisional biopsy; requests without prior tissue diagnosis do not meet the indication and may be denied.

    • Required documentation: prior tissue diagnosis by core or excisional biopsy (FNA not acceptable)
    • Supported codes: CPT 77049 or HCPCS C8908
    Prior Authorization

    Authorization required for pre‑operative bilateral MRI for biopsy‑proven malignant phyllodes

    Prior authorization is required when MRI Breast Bilateral without and with contrast (CPT 77049 or HCPCS C8908) is requested pre‑operatively for malignant phyllodes; the request must document the prior tissue diagnosis.

    • Codes to authorize: CPT 77049 or HCPCS C8908
    • Document prior core or excisional biopsy confirming malignant phyllodes
    Billing Rule

    CAD (C8937) not medically necessary with 77049/77048 unless used with C8908

    Do not bill HCPCS C8937 (CAD) with MRI Breast CPT 77049/77048 unless used with HCPCS C8908; CAD (C8937) with 77049/77048 without C8908 is not medically necessary and may be denied.

    Billing Rule

    Do not bill CPT 77021 with MRI‑guided breast biopsy (CPT 19085)

    Do not bill CPT 77021 (MR guidance for needle placement) in addition to MRI‑guided breast biopsy CPT 19085; CPT 19085 includes the imaging component and needle placement and CPT 77021 is not appropriate.

    Documentation Required

    Document the triggering reason and prior imaging when requesting MRI after screening

    When requesting an MRI to complete screening after mammogram/US, include the triggering reason (e.g., treating provider request, radiologist recommendation, or specific mammogram/US finding) and any pertinent prior imaging to support medical necessity.

    • Include radiologist report or treating provider request
    • Attach relevant mammogram/ultrasound findings (BI‑RADS category)
    Documentation Required

    Document lifetime‑risk calculation with accepted model for high‑risk MRI requests

    When requesting screening MRI for high‑risk individuals, document the clinical lifetime‑risk calculation using an accepted model (Gail, Tyrer‑Cuzick, BCSC, BOADICEA/CanRisk, or BRCAPRO) to justify eligibility.

    • Specify the risk model used and the calculated lifetime‑risk (≥20% required for MRI screening)
    • If applicable, document gene mutation status or prior chest radiation details with age/timing
    Documentation Required

    Documentation required for transmasculine supplemental screening requests

    Requests for supplemental annual ultrasound and/or MRI screening in transmasculine individuals must include documentation supporting transmasculine status, surgical history (reduction mammoplasty or absence of chest surgery), age ≥25, and an objective lifetime‑risk calculation demonstrating ≥20% lifetime risk.

    • Document surgical history (reduction mammoplasty, bilateral mastectomy, or none)
    • Provide lifetime‑risk model and result (≥20%)
    • Confirm patient age ≥25
    Documentation Required

    Include prior mammogram/ultrasound results and BI‑RADS in documentation

    Document prior diagnostic mammogram and/or breast ultrasound results including BI‑RADS category and clinical findings (e.g., palpable mass, skin changes, nipple symptoms) when requesting MRI or further imaging; lack of this information may jeopardize authorization.

    • Include BI‑RADS category from prior imaging
    • Describe clinical findings prompting imaging (palpable mass, discharge, skin change)
    Note
    Note

    Frequency and Surveillance Intervals

    MRI — BI-RADS 3 short-interval follow-up
    BI-RADS 3 MRI surveillance scheduleRepeat MRI at 6 months; if still BI-RADS 3, repeat at 12, 18, and 24 months; after 2 years of stability assess as benign (Category 2)
    First follow-up interval6 months after initial MRI BI-RADS 3
    Longer-term outcomeIf repeat imaging becomes BI-RADS 1 or 2, revert to routine screening per risk profile
    Ultrasound (CPT 76641/76642) — frequency
    Ultrasound repeat intervalRepeat breast ultrasound every 2-3 years after initial negative imaging
    Applicable CPT codesCPT 76641 (complete) and CPT 76642 (limited/follow-up)
    ContextRecommendation applies in implant surveillance pathways when initial imaging negative and implants placed >=5 years
    MRI Breast Bilateral (77049 / C8908) — frequency
    Recommended frequencyAnnual
    CodesCPT 77049 or HCPCS C8908 — MRI Breast Bilateral without and with contrast
    Indication summaryAnnual MRI is medically necessary for individuals meeting high-risk criteria (lifetime risk >=20% or specified genetic/radiation history) per guideline
    Ultrasound and/or MRI — annual frequency
    Recommended frequencyAnnual
    ModalitiesBreast ultrasound and/or MRI
    Population contextUsed as annual supplemental screening for transmasculine individuals meeting defined high-risk criteria (see guidelines)
    Ultrasound and/or MRI (supplemental screening) — frequency
    Supplemental screening frequencyAnnual
    Applicable codesCPT 76641/76642 (ultrasound) and CPT 77049 / HCPCS C8908 (MRI)
    Use caseAnnual supplemental screening when criteria for high-risk transgender screening are met

    Contrast Use Rules

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Not Medically Necessary / Investigational

    Routine CTA chest to evaluate recipient vessels for reconstruction is labeled NOT medically necessary. Gadolinium contrast is NOT medically necessary for implant integrity assessment in asymptomatic, average-risk individuals. In addition, a range of alternative breast imaging modalities (e.g., scintimammography, BSGI, PEM, thermography, impedance mammography, CT Breast/Cone Beam CT) are listed as investigational and are not supported for screening or diagnostic use.

    The guideline states that routine CTA chest specifically for recipient vessel evaluation in free-flap reconstruction (e.g., to map recipient internal mammary vessels) is NOT medically necessary; an exception may be considered when prior cardiac/vascular surgery or known chest vascular anomalies could affect operative planning.

    There is insufficient evidence to support routine pre-operative advanced imaging for pedicled flap reconstruction; therefore routine pre-operative imaging for pedicled flaps is not supported and is considered NOT medically necessary.

    The guideline lists multiple investigational breast imaging modalities that are not covered for screening or diagnosis, including nuclear breast imaging (scintimammography, BSGI, PET mammography/PEM), thermography, impedance mammography, CT Breast (CPT 0633T–0638T), and Cone Beam CT Breast.

    MRI has not been shown to reliably distinguish phyllodes tumor from fibroadenoma, and the guideline notes that MRI is not of value for that differential diagnosis; consequently MRI for that purpose is not supported and fine-needle aspiration (FNA) is not recommended for phyllodes diagnosis.

    Background and Scope

    These guidelines are evidence-based medical coverage policies developed by eviCore to guide determination of medical necessity and coverage for breast imaging services under Cigna-administered plans. They provide modality-, indication-, and code-specific guidance (including contrast rules and investigational exclusions) but are not treatment recommendations; the applicable benefit plan document governs final coverage decisions.

    Document structure — indication sections
    TOC breadthMultiple breast imaging indication sections present (e.g., MRI Breast Coding; Breast Reconstruction; MRI Indications; Nipple Discharge; Breast Pain; Alternative Imaging; Male Breast; Pregnancy/Lactation; Transgender Screening)
    Preface includedGeneral Considerations and BI-RADS reference charts included in preface
    Page referencesSections appear across the guideline TOC (pages listed in preface and section headings)
    Reference: ACR Appropriateness Criteria
    Referenced guideline setACR Appropriateness Criteria cited repeatedly for modality- and indication-specific recommendations
    PurposeACR criteria used as supporting evidence in risk, pregnancy, male breast, and other sections
    ExamplesACR Appropriateness Criteria on pregnancy, male breast imaging, palpable masses, and supplemental screening cited in references

    Definitions and Reference Terms

    Coverage policies — purpose and scope
    Intended useCoverage policies provide guidance used to interpret standard Cigna benefit plans and assist clinicians and medical directors in making medical necessity and coverage determinations
    Plan precedenceA customer's benefit plan document supersedes the coverage policy in case of conflict
    ScopeApplies to services/supplies managed by eviCore for Cigna per the Cigna CPT code list
    Table of contents — key entries
    TOC entries referencedIncludes BR-Preface and sections BR-6 through BR-12 among other section headings
    ExamplesNipple Discharge (BR-6), Breast Pain (BR-7), Alternative Imaging (BR-8), Male Breast (BR-9), Pregnancy/Lactation (BR-10), Transgender Screening (BR-12)
    Preface presenceGeneral Considerations and BI-RADS charts located in prefatory pages
    BI-RADS references in preface
    BI-RADS charts includedBI-RADS TM Categories Chart and BI-RADS TM Breast Density Categories are included in the preface
    Density categoriesA = Almost entirely fatty; B = Scattered fibroglandular densities; C = Heterogeneously dense; D = Extremely dense
    Category definitionsBI-RADS categories 0-6 described in guideline preface
    BI-RADS Categories — definitions
    BI-RADS categoriesStandardized assessment categories: 0 (Incomplete), 1 (Negative), 2 (Benign), 3 (Probably benign - short interval follow-up), 4 (Suspicious - consider biopsy), 5 (Highly suggestive of malignancy), 6 (Known biopsy-proven malignancy)
    Category 3 managementShort-interval imaging recommended (MRI-specific protocol provided elsewhere)
    Categories guide actionCategories 4-5 recommend biopsy rather than MRI to defer biopsy
    BI-RADS Breast Density — categories
    Density categories A-DA: Almost entirely fatty; B: Scattered fibroglandular densities; C: Heterogeneously dense; D: Extremely dense
    ImplicationBreast density referenced in supplemental screening recommendations (e.g., starting ages)
    PlacementDensity chart included in preface BI-RADS TM Breast Density Categories section
    Common donor sites / flap types
    Donor sites listedAbdomen (DIEP, MS TRAM, SIEA, free TRAM, pedicled TRAM), gluteal region (SGAP, IGAP), thigh (TUG/VUG/DUG/PAP), back (LD, TDAP, LAP)
    ContextReferenced for pre-operative vascular mapping in reconstruction planning
    SourceNCCN and evidence discussion cited in reconstruction section
    Accepted lifetime-risk models
    Accepted lifetime-risk modelsGail (NCI), Tyrer-Cuzick (IBIS), BCSC, BOADICEA/CanRisk, BRCAPRO
    UseRequired to document clinical lifetime-risk when requesting high-risk screening MRI
    ThresholdHigh-risk defined as lifetime risk >=20% per guideline
    Implant types — saline vs silicone
    Implant types overviewSaline implants: rupture often clinically apparent and resorbed; Silicone implants: ruptures less reliably detected on exam and may require imaging evaluation with ultrasound, mammogram, and/or MRI
    ImplicationImaging pathways differ by implant type — MRI less useful for saline in asymptomatic patients
    ReferenceImplant evaluation evidence discussion
    Physiologic nipple discharge — definition
    Physiologic nipple dischargeNon-spontaneous or multi-duct, lacks suspicious clinical findings; typically bilateral and often milky
    WorkupProlactin and TSH levels recommended for milky discharge; pituitary imaging not needed if prolactin normal
    Age-based imagingGuideline specifies different imaging approach by age for nipple discharge (see pathologic criteria)
    Pathologic nipple discharge — definition
    Pathologic nipple dischargeSpontaneous, unilateral, from a single duct, clear or bloody, persistent and reproducible
    SignificanceMay warrant imaging and different diagnostic pathway versus physiologic discharge
    Next stepsAge- and BI-RADS-dependent imaging algorithm described in guideline
    High-risk — definition and thresholds
    High-risk definitionIndividuals with lifetime breast cancer risk >=20% or specific risk factors (e.g., certain gene mutations, prior chest radiation) where supplemental MRI screening may be indicated
    Threshold for screeningAnnual MRI recommended when lifetime risk >=20% per accepted models
    Age/start rulesGene- and history-specific age thresholds provided (e.g., BRCA start at 25; others at 30-40 as noted)
    Pregnancy-associated breast cancer (PABC)
    PABC definitionBreast cancer diagnosed during pregnancy, throughout the first postpartum year, or during lactation
    Clinical noteUltrasound is first-line imaging for pregnant/lactating patients; IV gadolinium contraindicated in pregnancy
    Management implicationIf suspicion for malignancy in pregnancy, biopsy is next step rather than contrast MRI
    3D rendering — CPT codes and limits
    3D rendering CPTsCPT 76376 and CPT 76377
    LimitationsShould not be used with any 3D mammography code, not indicated for breast ultrasound, and should not be used with MRI Breast per guideline
    Coverage stance3D rendering restricted/limited per exclusions in guideline
    BI-RADS categories (1-5) — role in decisions
    BI-RADS decision useBI-RADS categories 1-5 are used as decision points: categories 1-3 may permit MRI if clinically suspicious; categories 4-5 indicate biopsy rather than MRI
    ExamplesSkin changes or nipple inversion with BI-RADS 1-3 may prompt MRI; BI-RADS 4-5 requires biopsy
    DocumentationBI-RADS category must be documented to support imaging pathway selection
    Malignant phyllodes — clinical notes
    Malignant phyllodes treatment noteMalignant phyllodes should be treated as a soft tissue sarcoma
    Diagnosis requirementDiagnosis requires tissue diagnosis by percutaneous core biopsy or excisional biopsy (FNA not recommended)
    MRI roleMRI supported pre-operatively to determine extent for malignant phyllodes after tissue diagnosis
    Diagnostic biopsy — required methods
    Diagnostic biopsy standardPercutaneous core biopsy or excisional biopsy required to establish diagnosis; FNA is inaccurate and not recommended
    Implication for MRIMRI indications tied to prior tissue diagnosis in phyllodes pathway
    ReferencePhyllodes background and evidence discussion

    Prior Authorization — Scope and Requirements

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Revision History